Learn how advanced context design and Claude Code elevate AI performance, turning tools into extraordinary problem-solvers.

Intellia has reported results from a phase 2 trial of its gene-editing drug for hereditary angioedema (HAE) that it says build the case for the drug as a phase 3 trial gets underway – but its shares ...